BR-cpd7

• Description:

  BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013) ; Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717) ) [1]

• UNSPSC:

  12352005

• Target:

  FGFR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/br-cpd7.html

• Concentration:

  10mM

• Purity:

  98.01

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  COC1=CC(OC)=C(C(NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)C5CCN(CC5)C(CNC6=CC=CC7=C6C(N(C7=O)C8CCC(NC8=O)=O)=O)=O)=NC=N2)C)=O)=C1Cl)Cl

• Molecular Formula:

  C44H47Cl2N11O8

• Molecular Weight:

  928.82

• References & Citations:

  [1]Kong Y, et al., A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity. Mol Cancer Ther. 2024 Jun 10:OF1-OF11.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported